There are more than 7,000 rare diseases with fewer than approximately 400 approved treatments. That’s just not good enough. This is why Cydan is focused on accelerating meaningful therapies for people with rare genetic diseases.
Cydan accelerates compelling science and develops that path for quickly and efficiently launching independent companies to bring those assets to patients.
Cydan is the first orphan drug accelerator, trusted for our commitment to patients, known for our understanding of science and sought after for our expertise in drug and business development.
Cydan Development, Inc., an orphan drug accelerator dedicated to creating therapies that improves the lives of people living with rare genetic diseases, today announced the launch of Imara, Inc.
Alone we are rare. Together we are strong.
We scour scientific literature, visit universities and attend medical conferences to identify potential compelling therapies.
Our rapid assessment with internal and external resources determines the path forward for this new clinical candidate.
An IND-ready asset is ready for Series A funding with a NewCo to bring this orphan drug candidate to patients.
Cydan NewCos have an investible corporate story, access to capital, experienced management and a
clear path forward.
Our Rare Disease Drug Development Model Cydan is focused on accelerating meaningful therapies for people with rare monogenic, non-oncologic diseases. We start with a compelling scientific idea or promising drug candidate from collaborators in academia and/or industry, and then efficiently advance the therapy through pre-clinical research to enable the establishment of an independent company to progress drug candidates through clinical and regulatory development to commercialization.View Our Collaborative Model
Cydan is focused on accelerating the development of meaningful therapies for people with rare genetic diseases, excluding oncology. Our goal is launching an independent company to drive the drug candidate through clinical and regulatory development to commercialization.Learn More